Societies always believed that affluence will bring wellbeing. But if you look at nations that have enjoyed long periods of affluence, such as the United States, they tell me that 70% of the adult population there is on prescription medicine. (Details read below, 1.) In Europe, which has enjoyed many decades of continuous affluence, 38% of the population suffers from mental illness.(Details read below 2.) If you just take away a few drugs from the market, a big portion of the population will go crazy. This is not wellbeing.
1.
"Often when people talk about health conditions they're talking about chronic conditions such as heart disease or diabetes," Dr. St. Sauver says. "However, the second most common prescription was for antidepressants — that suggests mental health is a huge issue and is something we should focus on. And the third most common drugs were opioids, which is a bit concerning considering their addicting nature."
Seventeen percent of those studied were prescribed antibiotics, 13 percent were taking antidepressants and 13 percent were on opioids. Drugs to lower lipids, such as cholesterol, came in fourth (11 percent) and vaccines were fifth (11 percent).
Drugs were prescribed to both men and women across all age groups, except high blood pressure drugs, which were seldom used before age 30.
Overall, women and older adults receive more prescriptions. Vaccines, antibiotics and anti-asthma drugs are most commonly prescribed in people younger than 19. Antidepressants and opioids are most common among young and middle-aged adults. Cardiovascular drugs are most commonly prescribed in older adults. Women receive more prescriptions than men across several drug groups, especially antidepressants: Nearly 1 in 4 women ages 50-64 are on an antidepressant.
For several drug groups, use increases with advancing age.
"As you get older you tend to get more prescriptions, and women tend to get more prescriptions than men," Dr. St. Sauver says.
Prescription drug use has increased steadily in the U.S. for the past decade. The percentage of people who took at least one prescription drug in the past month increased from 44 percent in 1999-2000 to 48 percent in 2007-08. Spending on prescription drugs reached $250 billion in 2009 the year studied, and accounted for 12 percent of total personal health care expenditures. Drug-related spending is expected to continue to grow in the coming years, the researchers say.
The study was funded by the National Institute on Aging and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
2.
1.
Nearly 7 in 10 Americans Take Prescription Drugs, Mayo Clinic, Olmsted Medical Center Find
June 19, 2013
CORRECTION: Corrects fourth most commonly prescribed drugs to drugs used to lower lipids rather than drugs to control blood pressure, and adds Olmsted Medical Center as study co-author.
ROCHESTER, Minn. — Nearly 70 percent of Americans are on at least one prescription drug, and more than half take two, Mayo Clinic and Olmsted Medical Center researchers say. Antibiotics, antidepressants and painkilling opioids are most commonly prescribed, their study found. Twenty percent of patients are on five or more prescription medications, according to the findings, published online in the journal Mayo Clinic Proceedings.
MULTIMEDIA ALERT: For audio and video of Dr. Jennifer St. Sauver talking about the study, visit the Mayo Clinic News Network.
The findings offer insight into prescribing practices. The statistics from the Rochester Epidemiology Project in Olmsted County, Minn. are comparable to those elsewhere in the United States, says study author Jennifer St. Sauver, Ph.D., a member of the Mayo Clinic Population Health Program in the Mayo Clinic Center for the Science of Health Care Delivery."Often when people talk about health conditions they're talking about chronic conditions such as heart disease or diabetes," Dr. St. Sauver says. "However, the second most common prescription was for antidepressants — that suggests mental health is a huge issue and is something we should focus on. And the third most common drugs were opioids, which is a bit concerning considering their addicting nature."
Seventeen percent of those studied were prescribed antibiotics, 13 percent were taking antidepressants and 13 percent were on opioids. Drugs to lower lipids, such as cholesterol, came in fourth (11 percent) and vaccines were fifth (11 percent).
Drugs were prescribed to both men and women across all age groups, except high blood pressure drugs, which were seldom used before age 30.
Overall, women and older adults receive more prescriptions. Vaccines, antibiotics and anti-asthma drugs are most commonly prescribed in people younger than 19. Antidepressants and opioids are most common among young and middle-aged adults. Cardiovascular drugs are most commonly prescribed in older adults. Women receive more prescriptions than men across several drug groups, especially antidepressants: Nearly 1 in 4 women ages 50-64 are on an antidepressant.
For several drug groups, use increases with advancing age.
"As you get older you tend to get more prescriptions, and women tend to get more prescriptions than men," Dr. St. Sauver says.
Prescription drug use has increased steadily in the U.S. for the past decade. The percentage of people who took at least one prescription drug in the past month increased from 44 percent in 1999-2000 to 48 percent in 2007-08. Spending on prescription drugs reached $250 billion in 2009 the year studied, and accounted for 12 percent of total personal health care expenditures. Drug-related spending is expected to continue to grow in the coming years, the researchers say.
The study was funded by the National Institute on Aging and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
2.
Nearly 40 percent of
Europeans suffer
mental illness
5 Min Read
LONDON (Reuters) - Europeans are plagued by mental and neurological illnesses, with almost 165 million people or 38 percent of the population suffering each year from a brain disorder such as depression, anxiety, insomnia or dementia, according to a large new study.
With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden — measured in the hundreds of billions of euros — as sufferers become too unwell to work and personal relationships break down.
“Mental disorders have become Europe’s largest health challenge of the 21st century,” the study’s authors said.
At the same time, some big drug companies are backing away from investment in research on how the brain works and affects behavior, putting the onus on governments and health charities to stump up funding for neuroscience.
“The immense treatment gap ... for mental disorders has to be closed,” said Hans Ulrich Wittchen, director of the institute of clinical psychology and psychotherapy at Germany’s Dresden University and the lead investigator on the European study.
“Those few receiving treatment do so with considerable delays of an average of several years and rarely with the appropriate, state-of-the-art therapies.”
Wittchen led a three-year study covering 30 European countries — the 27 European Union member states plus Switzerland, Iceland and Norway — and a population of 514 million people.
A direct comparison of the prevalence of mental illnesses in other parts of the world was not available because different studies adopt varying parameters.
Wittchen’s team looked at about 100 illnesses covering all major brain disorders from anxiety and depression to addiction to schizophrenia, as well as major neurological disorders including epilepsy, Parkinson’s and multiple sclerosis.
The results, published by the European College of Neuropsychopharmacology (ENCP) on Monday, show an “exceedingly high burden” of mental health disorders and brain illnesses, he told reporters at a briefing in London.
Mental illnesses are a major cause of death, disability, and economic burden worldwide and the World Health Organization predicts that by 2020, depression will be the second leading contributor to the global burden of disease across all ages.
Wittchen said that in Europe, that grim future had arrived early, with diseases of the brain already the single largest contributor to the EU’s burden of ill health.
The four most disabling conditions — measured in terms of disability-adjusted life years or DALYs, a standard measure used to compare the impact of various diseases — are depression, dementias such as Alzheimer’s disease and vascular dementia, alcohol dependence and stroke.
The last major European study of brain disorders, which was published in 2005 and covered a smaller population of about 301 million people, found 27 percent of the EU adult population was suffering from mental illnesses.
Although the 2005 study cannot be compared directly with the latest finding — the scope and population was different — it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year at that time. Wittchen’s team has yet to finalize the economic impact data from this latest work, but he said the costs would be “considerably more” than estimated in 2005.
The researchers said it was crucial for health policy makers to recognize the enormous burden and devise ways to identify potential patients early — possibly through screening — and make treating them quickly a high priority.
“Because mental disorders frequently start early in life, they have a strong malignant impact on later life,” Wittchen said. “Only early targeted treatment in the young will effectively prevent the risk of increasingly largely proportions of severely ill...patients in the future.”
With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden — measured in the hundreds of billions of euros — as sufferers become too unwell to work and personal relationships break down.
“Mental disorders have become Europe’s largest health challenge of the 21st century,” the study’s authors said.
At the same time, some big drug companies are backing away from investment in research on how the brain works and affects behavior, putting the onus on governments and health charities to stump up funding for neuroscience.
“The immense treatment gap ... for mental disorders has to be closed,” said Hans Ulrich Wittchen, director of the institute of clinical psychology and psychotherapy at Germany’s Dresden University and the lead investigator on the European study.
“Those few receiving treatment do so with considerable delays of an average of several years and rarely with the appropriate, state-of-the-art therapies.”
Wittchen led a three-year study covering 30 European countries — the 27 European Union member states plus Switzerland, Iceland and Norway — and a population of 514 million people.
A direct comparison of the prevalence of mental illnesses in other parts of the world was not available because different studies adopt varying parameters.
Wittchen’s team looked at about 100 illnesses covering all major brain disorders from anxiety and depression to addiction to schizophrenia, as well as major neurological disorders including epilepsy, Parkinson’s and multiple sclerosis.
Mental illnesses are a major cause of death, disability, and economic burden worldwide and the World Health Organization predicts that by 2020, depression will be the second leading contributor to the global burden of disease across all ages.
Wittchen said that in Europe, that grim future had arrived early, with diseases of the brain already the single largest contributor to the EU’s burden of ill health.
The four most disabling conditions — measured in terms of disability-adjusted life years or DALYs, a standard measure used to compare the impact of various diseases — are depression, dementias such as Alzheimer’s disease and vascular dementia, alcohol dependence and stroke.
The last major European study of brain disorders, which was published in 2005 and covered a smaller population of about 301 million people, found 27 percent of the EU adult population was suffering from mental illnesses.
Although the 2005 study cannot be compared directly with the latest finding — the scope and population was different — it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year at that time. Wittchen’s team has yet to finalize the economic impact data from this latest work, but he said the costs would be “considerably more” than estimated in 2005.
The researchers said it was crucial for health policy makers to recognize the enormous burden and devise ways to identify potential patients early — possibly through screening — and make treating them quickly a high priority.
“Because mental disorders frequently start early in life, they have a strong malignant impact on later life,” Wittchen said. “Only early targeted treatment in the young will effectively prevent the risk of increasingly largely proportions of severely ill...patients in the future.”
No comments:
Post a Comment